Advertisement

Comparison of treatment of early-stage breast cancer among Nurses’ Health Study participants and other Medicare beneficiaries

  • Andrea M. AustinEmail author
  • Nirav S. Kapadia
  • Gabriel A. Brooks
  • Tracy L. Onega
  • A. Heather Eliassen
  • Rulla M. Tamimi
  • Michelle Holmes
  • Qianfei Wang
  • Francine Grodstein
  • Anna N. A. Tosteson
Epidemiology
  • 75 Downloads

Abstract

Purpose

Increasingly epidemiological cohorts are being linked to claims data to provide rich data for healthcare research. These cohorts tend to be different than the general United States (US) population. We will analyze healthcare utilization of Nurses’ Health Study (NHS) participants to determine if studies of newly diagnosed incident early-stage breast cancer can be generalized to the broader US Medicare population.

Methods

Analytic cohorts of fee-for-service NHS–Medicare-linked participants and a 1:13 propensity-matched SEER–Medicare cohort (SEER) with incident breast cancer in the years 2007–2011 were considered. Screening leading to, treatment-related, and general utilization in the year following early-stage breast cancer diagnosis were determined using Medicare claims data.

Results

After propensity matching, NHS and SEER were statistically balanced on all demographics. NHS and SEER had statistically similar rates of treatments including chemotherapy, breast-conserving surgery, mastectomy, and overall radiation use. Rates of general utilization include those related to hospitalizations, total visits, and emergency department visits were also balanced between the two groups. Total spending in the year following diagnosis were statistically equivalent for NHS and SEER ($36,180 vs. $35,399, p = 0.70).

Conclusions

NHS and the general female population had comparable treatment and utilization patterns following diagnosis of early-stage incident breast cancers with the exception of type of radiation therapy received. This study provides support for the larger value of population-based cohorts in research on healthcare costs and utilization in breast cancer.

Keywords

Breast cancer Epidemiology Nurses’ Health Study Generalizability study 

Notes

Acknowledgements

We would like to thank the participants and staff of the Nurses’ Health Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

Author Contributions

All authors contributed to the study conception and design; AMA and QW analyzed the data. AMA, ANAT, and FG prepared the manuscript. All authors provided critical revisions to the manuscript.

Funding

Supported by the National Cancer Institute (Grant Number UM1CA186107).

Compliance with ethical standards

Conflict of interest

All the authors declare that they have no conflict of interest.

Research involving human and animal participants

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

This study utilizes retrospective, de-identified information. Informed consent was not necessary.

References

  1. 1.
    National Breast Cancer Foundation, Inc. (2016) Breast Cancer Facts. https://www.nationalbreastcancer.org/breast-cancer-facts. Accessed 22 Aug 2018
  2. 2.
    Kapadia NS, Austin AM, Carmichael DQ, Wang Q, Erekson ED, Feskanich D, Grodstein F, Tosteson AN, Bynum JPW (2018) Medicare utilization and spending among nurses compared to the general U.S. population. J. Women’s Health.  https://doi.org/10.1089/jwh.2017.6802 Google Scholar
  3. 3.
    Bronson MR, Kapadia NS, Austin AM, Wang Q, Feskanich D, Bynum JPW, Grodstein F, Tosteson ANA (2018) Leveraging linkage of cohort studies with administrative claims data to identify individuals with cancer. Med Care.  https://doi.org/10.1097/MLR.0000000000000875 Google Scholar
  4. 4.
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER–Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):IV-3-18Google Scholar
  5. 5.
    National Cancer Institute (2018) Cancer Diagnosis. https://training.seer.cancer.gov/disease/diagnosis/. Accessed 22 Aug 2018
  6. 6.
    Klabunde CN, Harlan LC, Warren JL (2006) Data sources for measuring comorbidity: a comparison of hospital records and Medicare claims for cancer patients. Med Care 44(10):921–928CrossRefGoogle Scholar
  7. 7.
    Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53(12):1258–1267CrossRefGoogle Scholar
  8. 8.
    Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D (2007) A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 17(8):584–590CrossRefGoogle Scholar
  9. 9.
    Mayo Clinic (2018) Patient Care and Health Info: Brachytherapy. https://www.mayoclinic.org/tests-procedures/brachytherapy/about/pac-20385159. Accessed 22 Aug 2018
  10. 10.
    Valle LF, Agarwal S, Bickel KE, Herchek HA, Nalepinski DC, Kapadia NS (2017) Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 162(3):409–417CrossRefGoogle Scholar
  11. 11.
    Takagi R, Komiya Y, Sutherland KL, Shirato H, Date H, Mizuta M (2018) Comparison of the average surviving fraction model with the integral biologically effective dose model for an optimal irradiation scheme. J Radiat Res 59(suppl_1):i32–i39CrossRefGoogle Scholar
  12. 12.
    Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399–424CrossRefGoogle Scholar
  13. 13.
    Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28(25):3083–3107CrossRefGoogle Scholar
  14. 14.
    Austin PC (2011) Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10(2):150–161CrossRefGoogle Scholar
  15. 15.
    Boero IJ, Gillespie EF, Hou J, Paravati AJ, Kim E, Einck JP, Yashar C, Mell LK, Murphy JD (2017) The impact of radiation oncologists on the early adoption of hypofractionated radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 97(3):571–580CrossRefGoogle Scholar
  16. 16.
    Lynge E, Ponti A, James T, Májek O, von Euler-Chelpin M, Anttila A, Fitzpatrick P, Frigerio A, Kawai M, Scharpantgen A et al (2014) Variation in detection of ductal carcinoma in situ (DCIS) during screening mammography: a survey within the International Cancer Screening Network (ICSN). Eur J Cancer (Oxf Engl 1990).  https://doi.org/10.1016/j.ejca.2013.1008.1013 Google Scholar
  17. 17.
    Braithwaite D, Mandelblatt JS, Kerlikowske K (2013) To screen or not to screen older women for breast cancer: a conundrum. Future Oncol (Lond Engl) 9(6):763–766CrossRefGoogle Scholar
  18. 18.
    Welch HG (2010) Screening mammography—a long run for a short slide? N Engl J Med 363(13):1276–1278CrossRefGoogle Scholar
  19. 19.
    Bekelman JE, Sylwestrzak G, Barron J, Liu J, Epstein AJ, Freedman G, Malin J, Emanuel EJ (2014) Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008–2013. JAMA 312(23):2542–2550CrossRefGoogle Scholar
  20. 20.
    Lairson DR, Parikh RC, Cormier JN, Chan W, Du XL (2015) Cost-effectiveness of chemotherapy for breast cancer and age effect in older women. Value Health J Int Soc Pharmacoecon Outcomes Res 18(8):1070–1078CrossRefGoogle Scholar
  21. 21.
    Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, Stolk L, Finucane HK, Sulem P, Bulik-Sullivan B et al (2015) Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat Genet 47(11):1294–1303CrossRefGoogle Scholar
  22. 22.
    Liu Y, Tobias DK, Sturgeon KM, Rosner B, Malik V, Cespedes E, Joshi AD, Eliassen AH, Colditz GA (2016) Physical activity from menarche to first pregnancy and risk of breast cancer. Int J Cancer 139(6):1223–1230CrossRefGoogle Scholar
  23. 23.
    Sisti JS, Collins LC, Beck AH, Tamimi RM, Rosner BA, Eliassen AH (2016) Reproductive risk factors in relation to molecular subtypes of breast cancer: results from the nurses’ health studies. Int J Cancer 138(10):2346–2356CrossRefGoogle Scholar
  24. 24.
    Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98(19):1406–1415CrossRefGoogle Scholar
  25. 25.
    Huang Z, Willett WC, Colditz GA, Hunter DJ, Manson JE, Rosner B, Speizer FE, Hankinson SE (1999) Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses’ Health Study. Am J Epidemiol 150(12):1316–1324CrossRefGoogle Scholar
  26. 26.
    Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A et al (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39(7):870–874CrossRefGoogle Scholar
  27. 27.
    Rice MS, Eliassen AH, Hankinson SE, Lenart EB, Willett WC, Tamimi RM (2016) Breast cancer research in the nurses’ health studies: exposures across the life course. Am J Public Health 106(9):1592–1598CrossRefGoogle Scholar
  28. 28.
    Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA (2005) Physical activity and survival after breast cancer diagnosis. JAMA 293(20):2479–2486CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Andrea M. Austin
    • 1
    Email author return OK on get
  • Nirav S. Kapadia
    • 1
    • 2
    • 3
  • Gabriel A. Brooks
    • 1
    • 2
    • 3
  • Tracy L. Onega
    • 1
    • 3
  • A. Heather Eliassen
    • 4
    • 5
  • Rulla M. Tamimi
    • 4
    • 5
  • Michelle Holmes
    • 5
  • Qianfei Wang
    • 1
  • Francine Grodstein
    • 4
    • 5
  • Anna N. A. Tosteson
    • 1
    • 2
    • 3
  1. 1.The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at DartmouthHanoverUSA
  2. 2.Department of MedicineDartmouth-Hitchcock Medical CenterLebanonUSA
  3. 3.Norris Cotton Cancer CenterLebanonUSA
  4. 4.Channing Division of Network Medicine, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  5. 5.Department of EpidemiologyHarvard T.H. Chan School of Public HealthBostonUSA

Personalised recommendations